Fosun Pharmaceutical (600196.SH) subsidiary furitinib succinate capsules approved for clinical trials

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (“Fosun Wanbang”), a holding subsidiary of the company, recently received approval from the State Drug Administration (“State Drug Administration”) for furitinib succinate capsules (project code: SAF-189, registration category: Class 1; “the new drug” for short) for use with anaplastic lymphoma kinase (ALK) positive or c-ros sarcoma carcinogenic factor-receptor tyrosine kinase (“new drug”) ROS1) positive stage IB to stage IIA is not small Approval of clinical trials for adjuvant treatment after radical tumor resection in patients with cellular lung cancer. Fosun Wanbang plans to conduct phase III clinical trials of the new drug in China (excluding Hong Kong, Macao and Taiwan regions of China; same below) when conditions are met.

The new drug is an innovative small molecule chemical drug, which is intended to be mainly used to treat non-small cell lung cancer (ALK+), non-small cell lung cancer (ROS1+), etc. The new drug was jointly conducted by Chongqing Fuchuang Pharmaceutical Research Co., Ltd., a holding subsidiary of the company, and the Shanghai Pharmaceutical Research Institute of the Chinese Academy of Sciences, and exclusively licensed Fosun Wanbang to exclusively develop (including but not limited to clinical trials, marketing registration, etc.) and commercialization of the new drug in China. Clinical studies up to now have shown good clinical efficacy in patients with advanced ALK-positive non-small cell lung cancer, remarkable curative effect on central nervous system metastases, and good safety.